Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Views - The company is focusing on chronic diseases, tumors, and immunology, covering four major business segments: pharmaceutical manufacturing, pharmaceutical commerce, medical aesthetics, and industrial microbiology. It is continuously optimizing its product structure and transitioning from generics to innovation. The core products of its subsidiary, China Medical East, are maintaining stable market sales and increasing market share. The medical aesthetics segment is showing growth potential, and the innovative pipeline is entering a harvest period. The projected net profit for 2025-2027 is estimated at 40.61 billion, 47.16 billion, and 55.37 billion yuan, with corresponding EPS of 2.32, 2.69, and 3.16 yuan, and PE ratios of 16.3, 14.0, and 11.9 times, respectively [7][8][10]. Summary by Sections Company Overview - The company, established in 1993 and listed in 1999, has developed into a large comprehensive pharmaceutical company covering the entire pharmaceutical industry chain. It has shifted its strategy towards research-driven innovation since 2018, optimizing its product structure and transitioning from generics to innovative products [18]. Business Performance - The company reported a revenue of 419.1 billion yuan in 2024, a year-on-year increase of 3.2%, and a net profit of 35.1 billion yuan, up 23.7% year-on-year. The pharmaceutical manufacturing segment generated 138.1 billion yuan in revenue, growing by 13.1%, while the medical aesthetics segment saw a slight decline in revenue [8][22]. Innovative Pipeline - The company is focusing on three core areas: tumors, endocrinology, and autoimmune diseases, with a differentiated layout in ADC and PROTAC technologies. The innovative pipeline includes over 80 projects, with several products entering clinical stages. The company aims to leverage its innovative capabilities to drive long-term growth [9][39][55]. Financial Summary - The company’s financial metrics show steady growth, with projected revenues of 44.68 billion, 47.95 billion, and 51.83 billion yuan for 2025, 2026, and 2027, respectively. The gross margin is expected to improve from 33.6% in 2025 to 35.4% in 2027, while the net margin is projected to increase from 9.1% to 10.7% over the same period [10][28].

Core Points - The company, Shanghai Bid Pharmaceutical Technology Co., Ltd., has announced a differentiated cash dividend distribution plan for the year 2024, proposing a cash dividend of 0.90 CNY per share (including tax) [2][4] - The total cash dividend to be distributed amounts to approximately 77.86 million CNY (including tax), based on a total share capital of 90,882,948 shares, after deducting 4,371,774 shares held in the company's repurchase account [2][3] - The company will not issue bonus shares or increase capital reserves, and the distribution will only involve cash dividends [2][3] Dividend Distribution Details - The cash dividend distribution will be based on the total share capital after deducting shares in the repurchase account, with each shareholder receiving 9.00 CNY for every 10 shares held [2][3] - The reference price for the ex-dividend trading will be calculated as the previous closing price minus the cash dividend of 0.86 CNY per share, with no change in the number of circulating shares [3] - The relevant dates for the dividend distribution include the record date, ex-dividend date, and cash dividend payment date, which are specified in the announcement [3] Tax Implications - For individual shareholders holding shares for more than one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.90 CNY per share [4][5] - For shares held for less than one year, the tax will be calculated upon transfer, with a 20% tax rate applied for shares held for one month or less, leading to a net distribution of 0.81 CNY per share after tax [5][6] - Qualified foreign institutional investors (QFII) will have a 10% corporate income tax withheld, resulting in a net distribution of 0.81 CNY per share [6][7] Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's secretariat at 021-61601560 [8]

Core Viewpoint - The article discusses the recent shareholding changes of Su Xin Fund and Zhen Jin Investment in Hao Yuan Pharmaceutical, highlighting their reduction in shareholding and the company's financial performance expectations for 2024 [1][3][4]. Shareholding Changes - Su Xin Fund's shareholding has decreased to 10.548 million shares, representing 5% of the company, thus no longer being a major shareholder [1] - Su Xin Fund plans to reduce up to 6.3288 million shares, accounting for 3% of the total share capital, from March 18 to June 17 [2] - Zhen Jin Investment has completed its reduction of 3.1955 million shares, which is 1.51% of the total share capital, from February 28 to May 22 [2][3] Financial Performance Expectations - Hao Yuan Pharmaceutical anticipates a revenue of CNY 2.1 billion to CNY 2.3 billion for 2024, reflecting a year-on-year growth of 11.70% to 22.34% [4] - The expected net profit attributable to shareholders is projected to be between CNY 185 million and CNY 210 million, indicating a growth of 45.16% to 64.77% [4] - The company attributes its profit growth to the strong performance of its high-margin life science reagent business, which has seen an increase in revenue share compared to 2023 [4] Market Performance - As of May 30, Hao Yuan Pharmaceutical's stock price increased by 15.26% to CNY 44.10 per share, with a market capitalization of CNY 9.303 billion, and has risen over 107% in the past year [5] - The stock's trading volume on the last trading day was 13.5295 million shares, with a turnover rate of 6.56% [6]

随着上市公司2024年年报与2025年一季报披露工作正式收官，5月以来，A股机构评级次数愈发频繁。 据证券时报·数据宝统计，5月内71家机构合计进行了5151次评级，共计1859只个股被券商研报给予"买入型"评级（包括买入、增持、强烈推荐、推荐）。 医药、食饮、电力设备行业 机构关注度较高 根据机构数量划分，上述个股中，共计316股获得5家及以上机构参与评级。从行业上看，这316股广泛分布于医药生物、食品饮料、电力设备等申万行 业，上榜个股数量均在30只以上；汽车和电子也有多股获评，数量均超过25只。 申万医药生物指数5月累计上涨6.42%，位于一级行业指数涨幅第二位。细分赛道中，化学制药、生物制品、医疗服务等涨幅靠前，均超过5%。 个股中，舒泰神以145.37%的月涨幅居首。公司属创新药领域，其控股子公司江苏贝捷泰的"注射用STSP-0601"进入国家药品监督管理局药品审评中心 （NMPA）"拟优先审评品种公示"，市场关注度较高。此外，龙头企业包括恒瑞医药、迈瑞医疗、药明康德等均录得不错的涨幅。 中信建投证券指出，"三医联动"顶层制度设计的改革措施已经逐步落地。医药领域的改革政策已进入常态化阶段；医保领域是 ...

《上市公司股东会规则》 《上市公司治理准则》 《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》和《浙江医药股份有限公司 章程》(以下简称《公司章程》)的规定，特制定本议事规则。 浙江医药股份有限公司 第十届六次董事会审议的内控制度汇编 目 录 股东会议事规则 第一章 总 则 第一条 为规范浙江医药股份有限公司(以下简称公司)行为，保证股东会依法行 使职权，根据《中华人民共和国公司法》(以下简称《公司法》)、《中华人民共和国 证券法》 （以下简称《证券法》）、 第二条 公司应严格按照法律、行政法规、《公司章程》及本规则的相关规定召 开股东会，保证股东能够依法行使权利。 公司董事会应切实履行职责，认真、按时组织股东会。公司全体董事应勤勉尽责， 确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 本议事规则适用于公司年度股东会和临时股东会（以下统称"股东会"）。 年度股东会每年召开一次，应当于上一会计年度结束后的 6 个月内举行。临时股东会 不定期召开，出现《公司法》规定的应当召开临时股东会的情形时，临时股东会应当 在 2 个月内召开。 公司 ...

证券代码：600216 证券简称：浙江医药 公告编号：2025-021 浙江医药股份有限公司 关于取消监事会并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）于2025年5月30日以通讯表决 方式召开了第十届六次董事会会议，审议通过了《关于取消监事会并修订 <公司> 章程>的议案》。根据《中华人民共和国公司法》《上市公司章程指引》等相关规 定，结合公司实际情况，公司不再设置监事会，监事会的职权由董事会审计委员 会行使，公司《监事会议事规则》等监事会相关制度相应废止，同时修订《公司 章程》及公司部分制度中涉及监事、监事会、股东会名称相关表述。 《公司章程》 主要修订情况如下： 《公司章程》原条文 《公司章程》修订后的条文 第一条 为维护公司、股东和债权人的 第一条 为维护公司、股东、职工和债 合法权益，规范公司的组织和行为，根 权人的合法权益，规范公司的组织和行 据《中华人民共和国公司法》（以下简 为，根据《中华人民共和国公司法》（以 称《公司法》）、《中华人 ...

每经记者｜肖芮冬 每经编辑｜赵云 5 月 30 日，市场全天震荡调整，创业板指领跌。截至收盘，沪指跌 0.47% ，深成指跌 0.85% ，创业板指跌 0.96% 。 板块方面，猪肉、创新药、银行、 CRO 等板块涨幅居前，黄金、草甘膦、可控核聚变、人形机器人、环 保设备、消费电子等板块跌幅居前。 再次，从实际走势来看，主要股指的日内低点都出现在上午10点前后，后续跌幅收窄，转为震荡走势； 截至收盘，市场昨日涨幅并未完全回吐，两个交易日仍累计上涨。 全市场超 4100 只个股下跌。沪深两市全天成交额 1.14 万亿元，较上个交易日缩量 462 亿。 昨天刚走出大阳线，今天，5月最后一个交易日，A股就出现回调。如何理解？ 我们认为，这里仍适合以平常心看待，理由有四： 首先，昨日之前，市场普遍对端午节前后行情持谨慎态度，突如其来的大涨反而有些超预期，也稍稍大 家拔高对后市的期待值； 其次，今天市场的回调，一定程度上受到"美国上诉法院暂时恢复实施特朗普政府关税政策"消息的影 响，毕竟其抵消了昨天上涨的部分动因； 最后，拉长到周线、月线维度，市场横盘震荡的趋势没有改变，以这样的状态结束5月行情，进入6月， 市场或迎来 ...

Market Overview - The Asia-Pacific markets collectively declined, with the Nikkei 225 and the Korea Composite Index dropping nearly 1%, and the Hang Seng Index falling by 1.5% during intraday trading [1] - The A-share market also saw all three major indices decline, with several high-priced stocks like Wangzi New Materials and Yong'an Pharmaceutical hitting the daily limit down [2] High-priced Stocks Plummet - High-priced stocks experienced significant drops, with Wangzi New Materials hitting the daily limit down at a price of 19.67 CNY per share, reflecting a decline of 9.98% [4][5] - Yong'an Pharmaceutical also faced a daily limit down, citing a significant deviation from its fundamentals and warning of high speculation risks [7] - Other high-priced stocks such as Shangwa Co., Guofang Group, and others also reported substantial declines [13] Innovation Drug Sector Strengthens - The pharmaceutical sector, particularly innovative drugs, saw a strong performance, with companies like Ruizhi Pharmaceutical and Nuo Si Lan De rising over 15% [15] - The National Medical Products Administration recently approved 11 new drug listings, covering various therapeutic areas, which has contributed to the positive sentiment in the sector [19] - Analysts believe that the pharmaceutical sector is supported by four key factors: ongoing demand for healthcare, increasing global competitiveness of domestic innovative drugs, signs of profit reversal, and low valuations in the innovative drug sector [20][21] Livestock Sector Leads Gains - The livestock sector led the market gains, with pig and chicken farming concepts showing the highest increases, including stocks like Juxing Agriculture and Xiangjia Co. hitting the daily limit up [23] - Recent legislative efforts in Shanghai and Sichuan aim to support the development of the livestock industry, which may further bolster the sector [26]

Group 1 - Guangyang Co., Ltd. has decided to terminate the plan to acquire 100% equity of Ningbo Yinqiu Technology Co., Ltd. and will resume trading on May 30, 2025 [1] - Longjing Environmental Protection plans to invest 75.075 million yuan to acquire 20% equity in Zhejiang Jitai Intelligent Technology Co., Ltd. [1] - Fengmao Co., Ltd. intends to invest up to 1.5 billion yuan to establish an automotive parts production base in Jiaxing [2] Group 2 - JinkoSolar has received a government subsidy of 98 million yuan [2] - Huayuan Real Estate has completed the registration of its name change to "Huayuan Holdings," effective June 5, 2025 [2][3] - Haisen Pharmaceutical's general manager plans to reduce his stake by 0.97% of the company's total shares [4][5] Group 3 - Shandong Highway plans to issue bonds not exceeding 8 billion yuan [6] - Mengguli's shareholders plan to collectively reduce their stake by up to 5% [7] - Yihua Tong has terminated its fuel cell comprehensive testing evaluation center project, originally planned for 220 million yuan [9] Group 4 - Ouma Software is the first candidate for the banking industry association's professional qualification examination service project, with a bid of 39.90 yuan per subject [11] - ST Dehao's subsidiary plans to invest 50 million yuan in an automotive LED packaging project [11] - Shuanglin Co., Ltd. plans to raise no more than 1.5 billion yuan through a private placement [12] Group 5 - Huaci Co., Ltd. plans to raise no more than 700 million yuan for the ASEAN Ceramic Valley project [13] - Aisi Kai intends to sign a procurement framework agreement for ceramic 3D printers, not exceeding 7.5 million yuan [14] - Baolingbao's major shareholder plans to reduce their stake by up to 3% [15] Group 6 - Heng Rui Pharmaceutical's subsidiary has received conditional approval for the launch of a class 1 innovative drug for lung cancer treatment [16][17] - *ST Jinguang is facing delisting due to continuous false reporting in annual reports from 2020 to 2023 [18] - Guangxi Broadcasting plans to swap 100% equity of Guangdian Technology for 51% equity of Jiaoke Group, with both assets valued at 1.411 billion yuan [19][20] Group 7 - ST Ruike's stock will be delisted from risk warnings and will change its name to "Guorui Technology" effective June 3, 2025 [21][22]

编号：2025-006 | | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他（请文字说明其他活动内容） | | 参与单位名称 | 中国银河证券：王晓磊、翟启迪 | | 及人员姓名 | | | 时间 | 2025 年 5 月 29 日 | | 地点 | 博苑股份会议室 | | 上市公司接待 | 1、董事会秘书：张山岗 | | 人员姓名 | 2、财务总监：孙腾 | | | 3、证券事务代表：杨艳丽 1、公司无机碘化物产品的市场前景？ | | | 答：从下游主要需求领域角度看，无机碘化物产品市场前 | | | 景广阔。 | | | （1）医药领域应用与需求 | | | 随着生活水平提高、人口老龄化加剧及健康意识增强，人 | | 投资者关系活 | 均医疗支出预计将持续增长。在肿瘤、心血管疾病和神经系统 | | 动主要内容介 | 疾病诊断领域（如 和 MRI），X 射线造影剂需求将稳步提升， CT | | 绍 | 推动国内造影剂市场规模扩大。同时，进口替代和产品升级将 | | | ...